Multiple contributing host (age, sex, genetic predisposition), tumour (type and latency period), and treatment (organ irradiation, chemotherapy) risk factors for subsequent neoplasia complicate determining whether there is a specific risk from GH replacement (72, 74). Here, GH1 is linked to neoplasm.